327 related articles for article (PubMed ID: 34895470)
41. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
[TBL] [Abstract][Full Text] [Related]
42. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.
Kanie T; Mizuno A; Takaoka Y; Suzuki T; Yoneoka D; Nishikawa Y; Tam WWS; Morze J; Rynkiewicz A; Xin Y; Wu O; Providencia R; Kwong JS
Cochrane Database Syst Rev; 2021 Oct; 10(10):CD013650. PubMed ID: 34693515
[TBL] [Abstract][Full Text] [Related]
43. Interventions for weight loss in people with chronic kidney disease who are overweight or obese.
Conley MM; McFarlane CM; Johnson DW; Kelly JT; Campbell KL; MacLaughlin HL
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013119. PubMed ID: 33782940
[TBL] [Abstract][Full Text] [Related]
44. Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette's syndrome: a systematic review and network meta-analysis.
Farhat LC; Behling E; Landeros-Weisenberger A; Levine JLS; Macul Ferreira de Barros P; Wang Z; Bloch MH
Lancet Child Adolesc Health; 2023 Feb; 7(2):112-126. PubMed ID: 36528030
[TBL] [Abstract][Full Text] [Related]
45. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S
Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878
[TBL] [Abstract][Full Text] [Related]
46. Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management.
Fujioka K; Braverman-Panza J
J Fam Pract; 2016 Jul; 65(7 Suppl):S16-23. PubMed ID: 27565106
[TBL] [Abstract][Full Text] [Related]
47. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Knop FK; Aroda VR; do Vale RD; Holst-Hansen T; Laursen PN; Rosenstock J; Rubino DM; Garvey WT;
Lancet; 2023 Aug; 402(10403):705-719. PubMed ID: 37385278
[TBL] [Abstract][Full Text] [Related]
48. Meta-analysis: pharmacologic treatment of obesity.
Li Z; Maglione M; Tu W; Mojica W; Arterburn D; Shugarman LR; Hilton L; Suttorp M; Solomon V; Shekelle PG; Morton SC
Ann Intern Med; 2005 Apr; 142(7):532-46. PubMed ID: 15809465
[TBL] [Abstract][Full Text] [Related]
49. Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis.
Tan B; Pan XH; Chew HSJ; Goh RSJ; Lin C; Anand VV; Lee ECZ; Chan KE; Kong G; Ong CEY; Chung HC; Young DY; Chan MY; Khoo CM; Mehta A; Muthiah MD; Noureddin M; Ng CH; Chew NWS; Chin YH
Int J Obes (Lond); 2023 Aug; 47(8):677-685. PubMed ID: 37253796
[TBL] [Abstract][Full Text] [Related]
50. Green tea for weight loss and weight maintenance in overweight or obese adults.
Jurgens TM; Whelan AM; Killian L; Doucette S; Kirk S; Foy E
Cochrane Database Syst Rev; 2012 Dec; 12(12):CD008650. PubMed ID: 23235664
[TBL] [Abstract][Full Text] [Related]
51. Pharmacotherapy for obesity.
Ioannides-Demos LL; Proietto J; McNeil JJ
Drugs; 2005; 65(10):1391-418. PubMed ID: 15977970
[TBL] [Abstract][Full Text] [Related]
52. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
Rubino D; Abrahamsson N; Davies M; Hesse D; Greenway FL; Jensen C; Lingvay I; Mosenzon O; Rosenstock J; Rubio MA; Rudofsky G; Tadayon S; Wadden TA; Dicker D;
JAMA; 2021 Apr; 325(14):1414-1425. PubMed ID: 33755728
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide in Overweight or Obese Adults: A Systematic Review with Meta-Analysis.
Dorneles G; Algeri E; Lauterbach G; Pereira M; Fernandes B
Exp Clin Endocrinol Diabetes; 2024 Jun; 132(6):316-327. PubMed ID: 38599612
[TBL] [Abstract][Full Text] [Related]
54. Pharmacotherapy of obesity: Available medications and drugs under investigation.
Pilitsi E; Farr OM; Polyzos SA; Perakakis N; Nolen-Doerr E; Papathanasiou AE; Mantzoros CS
Metabolism; 2019 Mar; 92():170-192. PubMed ID: 30391259
[TBL] [Abstract][Full Text] [Related]
55. Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Wilding JPH; Batterham RL; Calanna S; Davies M; Van Gaal LF; Lingvay I; McGowan BM; Rosenstock J; Tran MTD; Wadden TA; Wharton S; Yokote K; Zeuthen N; Kushner RF;
N Engl J Med; 2021 Mar; 384(11):989-1002. PubMed ID: 33567185
[TBL] [Abstract][Full Text] [Related]
56. Effect of orlistat on glycaemic control in overweight and obese patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.
Aldekhail NM; Logue J; McLoone P; Morrison DS
Obes Rev; 2015 Dec; 16(12):1071-80. PubMed ID: 26345590
[TBL] [Abstract][Full Text] [Related]
57. Efficacy and safety of once weekly semaglutide 2ยท4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial.
Mu Y; Bao X; Eliaschewitz FG; Hansen MR; Kim BT; Koroleva A; Ma RCW; Yang T; Zu N; Liu M;
Lancet Diabetes Endocrinol; 2024 Mar; 12(3):184-195. PubMed ID: 38330988
[TBL] [Abstract][Full Text] [Related]
58. Formulary management of 2 new agents: lorcaserin and phentermine/topiramate for weight loss.
Kelly EM; Tungol AA; Wesolowicz LA
J Manag Care Pharm; 2013 Oct; 19(8):642-54. PubMed ID: 24074010
[TBL] [Abstract][Full Text] [Related]
59. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.
Wadden TA; Bailey TS; Billings LK; Davies M; Frias JP; Koroleva A; Lingvay I; O'Neil PM; Rubino DM; Skovgaard D; Wallenstein SOR; Garvey WT;
JAMA; 2021 Apr; 325(14):1403-1413. PubMed ID: 33625476
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
